日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and polymyalgia rheumatica

更正:DANIsh VASculitis队列研究:一项全国多中心前瞻性研究方案,纳入巨细胞动脉炎和风湿性多肌痛的新发和既往患者

Nielsen, Berit D; Kristensen, Salome; Donskov, Agnete; Terslev, Lene; Dreyer, Lene Wohlfahrt; Colic, Ada; Hetland, Merete Lund; Højgaard, Pil; Ellingsen, Torkell; Hauge, Ellen-Margrethe; Chrysidis, Stavros; Keller, Kresten K

BRD1 haploinsufficiency alters early neuronal programming and disrupts maturation in human induced glutamatergic neurons.

BRD1 单倍体不足会改变早期神经元编程,并破坏人类诱导谷氨酸能神经元的成熟。

Qvist Per, Donskov Julie, Deans P J, Pediotidis-Maniatis Dimitrios, Høgfeldt Jacob, Borglum Anders, Denham Mark, Brennand Kristen

Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: A Narrative Review of Clinical Trials

微生物组和饮食在癌症检查点免疫疗法反应中的作用:临床试验的叙述性综述

Gamrath, Lone; Pedersen, Tobias Bruun; Møller, Martin Vad; Volmer, Lone Marie; Holst-Christensen, Linda; Vestermark, Lene Weber; Donskov, Frede

Soluble CD206 in metastatic renal cell carcinoma: Relation to clinical-biochemical parameters and patient outcome

转移性肾细胞癌中可溶性CD206:与临床生化参数和患者预后的关系

Lauridsen, Kasper Munch; Møller, Holger Jon; Kristensen, Mie Wolff; Fristrup, Niels; Donskov, Frede; Hokland, Marianne; Andersen, Morten Nørgaard

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

对转移性肾细胞癌患者进行酪氨酸激酶抑制剂(TKI)治疗药物监测(TDM)以优化疗效。TKI-TDM试验。研究方案

Henriksen, Jakob N; Andersen, Charlotte U; Donskov, Frede; Hoffmann-Lücke, Elke; Greibe, Eva; Fristrup, Niels

Socioeconomic equality in initiation of biologic treatment in Danish patients with inflammatory bowel disease

丹麦炎症性肠病患者生物制剂治疗启动中的社会经济平等

Petersen, Sofie Ronja; Fogh Rasmussen, Nathalie; Overgaard Donskov, Agnete; Thygesen, Lau Caspar; Olsen, Kim Rose; Juel Ahrenfeldt, Linda; Andersen, Vibeke

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:来自 III 期 CheckMate 214 试验的 8 年延长随访疗效和安全性结果

Tannir, N M; Albigès, L; McDermott, D F; Burotto, M; Choueiri, T K; Hammers, H J; Barthélémy, P; Plimack, E R; Porta, C; George, S; Donskov, F; Atkins, M B; Gurney, H; Kollmannsberger, C K; Grimm, M-O; Barrios, C; Tomita, Y; Castellano, D; Grünwald, V; Rini, B I; Jiang, R; Desilva, H; Fedorov, V; Lee, C-W; Motzer, R J

Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer

改良型转移性乳腺癌分期系统的开发和方法学验证

Berg, Tobias; Jensen, Maj-Britt; Rossing, Maria; Bechmann, Troels; Donskov, Frede; Knoop, Ann Søegaard; Ejlertsen, Bent

Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium

一线联合免疫疗法治疗转移性肾细胞癌患者时,绝对淋巴细胞计数的预后意义:来自国际转移性肾细胞癌数据库联盟的结果

Takemura, K; Yuasa, T; Lemelin, A; Ferrier, E; Wells, J C; Saad, E; Saliby, R M; Basappa, N S; Wood, L A; Jude, E; Pal, S K; Donskov, F; Beuselinck, B; Szabados, B; Powles, T; McKay, R R; Gebrael, G; Agarwal, N; Choueiri, T K; Heng, D Y C

Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis

针对部分原发性转移性肾细胞癌患者的细胞减灭性肾切除术:一项全国性综合结果分析

Azawi, Nessn; Geertsen, Louise; Nadler, Naomi; Mosholt, Karina Sif Soendergaard; Axelsen, Sofie Staal; Christensen, Jane; Jensen, Niels Viggo; Fristrup, Niels; Dalton, Susanne Oksbjerg; Donskov, Frede; Lund, Lars